Member News
Health Canada Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Adult Patients with Resectable Stage II, IIIA, or IIIB (T3-4N2) Non-small Cell Lung Carcinoma (NSCLC) in Combination with Platinum-containing Chemotherapy as Neoadjuvant Treatment, and then Continued as Monotherapy as Adjuvant Treatment After Surgery
Approval is based on the Phase 3 KEYNOTE-671 Trial KIRKLAND, QC – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Health Canada has… Read More
